---
title: "Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286808518.md"
description: "Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News"
datetime: "2026-05-18T10:55:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286808518.md)
  - [en](https://longbridge.com/en/news/286808518.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286808518.md)
---

# Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

### Related Stocks

- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)

## Related News & Research

- [SVRA: MOLBREEVI shows strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market](https://longbridge.com/en/news/295577539.md)
- [Savara merilis presentasi korporasi tentang penyakit paru langka autoimmune PAP dan kandidat terapi inhalasi MOLBREEVI](https://longbridge.com/en/news/295577813.md)
- [Savara posts corporate presentation focused on autoimmune pulmonary alveolar proteinosis and MOLBREEVI program](https://longbridge.com/en/news/292798258.md)
- [Inhalation Sciences holds extraordinary shareholder meeting, approves TO4 warrant issue to lenders](https://longbridge.com/en/news/296223507.md)
- [Volare opens commercial-scale insect protein plant in Pori with EUR 15 million investment](https://longbridge.com/en/news/296203318.md)